Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

Krystal Biotech Earnings Call: Key Takeaways

Krystal Biotech delivered strong Q3 revenue growth of 30% and profitability, though clinical timelines for several pipeline programs were pushed to 2027, prompting a $400 million share repurchase authorization.

Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Revenue GrowthGlobal revenue $127.3M (+30%); US $95.3M; International $32M.
Mgmt ConfidenceHigh confidence in Vyjuvek's long-term growth and intrinsic stock value.
Demand VisibilityStrong demand with 760+ US reimbursement approvals and 80 new prescribers.
Margin TrendsGross margin 94%, down from 96% due to international launch costs.
Op. LeverageGrowing commercial business funding global expansion and R&D pipeline internally.
Pricing PowerSecured pricing in Japan, Germany, and Italy; Spain decision expected year-end.
Vol vs PriceGrowth driven by expanding prescriber network and international market entries.
Segment GrowthInternational revenue reached $32M; US remains primary driver at $95.3M.
New ClientsAdded 80 new US prescribers; 20+ centers active in Germany.
Capex & Debt$1.2B cash; $400M share repurchase authorized over next two years.
RegulatoryEngaging FDA on KB113; complex innovative design meeting for CF program.
CommentaryFocusing on disciplined capital allocation between R&D and returning shareholder capital.
New LaunchesItaly launch expected early 2027; Spain launch potential in 2025.

Growth

Total revenue reached $127.3 million, up 30% YoY; US revenue contributed $95.3 million.

Outlook

Expects Italy launch in early 2027 and multiple clinical readouts throughout 2027.

Risks

Management pivoted on specific enrollment numbers for NK and CF trials, citing stringent criteria and delays.

Source

The company's earnings call, NASDAQ: KRYS, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

Krystal Biotech, Inc.: key numbers

Share price
$297.90Close, Nov 16
Market cap
$8.83B
Shares outstanding
29.63MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Krystal Biotech, Inc.

All →
7:07 AM ET 8-K
Financial Results

Krystal Biotech Financial Results

Krystal Biotech reported third quarter 2026 financial results, highlighted by $127.3 million in global VYJUVEK net product revenue, a 30% year-over-year increase. The company ended the quarter with a strong cash position of $1.2 billion and announced a new $400 million share repurchase program. Additionally, the company completed pricing negotiations for VYJUVEK in Germany and Italy and reported positive clinical data for its KB113 candidate in Gorlin syndrome.

“Continued growth in VYJUVEK revenue is supporting profitability and funding the advancement of our pipeline. Our financial strength allows us to invest fully in these programs and our global commercial expansion while returning capital to shareholders. The $400 million share repurchase program, under which we expect to repurchase shares opportunistically over the next two years, reflects our confidence in Krystal’s long-term growth prospects and our commitment to disciplined capital allocation.”

Krish S. Krishnan, Chairman and Chief Executive Officer
7:06 AM ET 10-Q
Financial Results ▶ Call

Krystal Biotech Q3 2026 Results: Net Income $63.1M, Down 20.5% YoY

Krystal Biotech reported a strong third quarter in 2026, with product revenue increasing to $127.3 million compared to $97.8 million in the prior year. Net income for the nine months ended September 30, 2026, rose to $173.8 million, supported by significant growth in cash and investments totaling over $1.19 billion.

Key figure
Net income $63.1M · -20.5% YoY
7:02 AM ET 8-K
Clinical Trial Data

Krystal Biotech Clinical Trial Data

Krystal Biotech announced positive proof-of-concept clinical data from its Gorlin Syndrome Pilot Study evaluating KB113 for the treatment of basal cell carcinomas. The study showed that over 80% of assessed lesions regressed across three patients, including non-injected lesions, suggesting a systemic abscopal effect.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.